Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + niraparib
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Abemaciclib + niraparib is an investigational oral combination therapy consisting of two small molecule drugs: abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, and niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor. Abemaciclib inhibits CDK4/6 to block cell cycle progression in cancer cells, while niraparib impairs DNA repair by inhibiting PARP enzymes. The combination aims to enhance antitumor activity by simultaneously disrupting cell proliferation and DNA repair mechanisms. This regimen is being studied primarily for late-line treatment of ovarian cancer and as neoadjuvant therapy in hormone receptor-positive, HER2-negative breast cancer[1][2][3][4].
- Other names
- abemaciclib + niraparib
02
Targets
CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on abemaciclib + niraparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + niraparib.